Join
Live feed
·
PRReleasevia Quantisnow
X4 Pharmaceuticals Inc. logo

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
XFOR· X4 Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XFOR (X4 Pharmaceuticals Inc.) and more on Quantisnow.